Denali: can drug treatments defeat the blood-brain barrier?
Claire Shaw – Portfolio Director
- Denali is engineering drugs to cross the blood-brain barrier to treat Alzheimer’s and other neurodegenerative diseases
- It uses transferrin receptors to bypass the blood-brain barrier's security measures
- If successful, it could have a wide-reaching impact on patients and investors
As with any investment, your capital is at risk.
About 98 per cent of small molecule drugs can’t cross the blood-brain barrier (BBB), which is a network of blood vessels and tissues designed to keep toxins out of the brain.
Denali Therapeutics is dedicated to defeating neurodegenerative diseases. It's developing drugs to cross the barrier and target 'degenogenes', or genes that, when they mutate, cause brain diseases like Alzheimer's.
Neurological drug trials have historically been the graveyard of drug development. Most drugs can’t cross the blood-brain barrier, a layer of cells that acts as a filter, keeping harmful things out and beneficial things within the brain. That has made it very difficult to treat diseases such as Alzheimer’s and Parkinson’s.
Fortunately, new developments offer hope. This graphic from Scottish Mortgage shows how one of its portfolio companies, Denali Therapeutics, is engineering drugs that can potentially reach the brain.
What is the blood-brain barrier?
The body has a special shield of blood vessels and tissues known as the blood-brain barrier. You can think of it as a strong wall with tiny security guards that only allow certain things to go from your blood into your brain. It’s very picky about what it lets in to keep out germs and toxins.
However, the blood-brain barrier makes it very challenging to treat brain diseases. Drugs have historically been unable to cross the barrier.
Engineering brain delivery
To tackle this problem, Denali Therapeutics is developing drugs better positioned to cross the blood-brain barrier. Here’s how it works:
- Transferrin is a naturally occurring protein that carries molecules such as iron into the brain by binding to transferrin receptors. The receptors are like a VIP pass that allows the molecules to pass through the barrier’s security guards.
- Denali’s small molecule drugs bind to these transferrin receptors using transport vehicles, such as antibodies or enzymes.
- By binding to these receptors, Denali hopes its drugs can sneak through the blood-brain barrier and into the brain.
To hear more about how Denali is revolutionising treatment of neurogenerative diseases, check out our podcast episode with CEO and Founder Ryan Watts.
The company has several drug candidates in various clinical trial stages. Through studying ‘degenogenes’ – genes that cause neurodegeneration when they mutate – Denali can develop drugs that target a future where degenerative diseases are defeated.
An opportunity for investors
If Denali develops effective treatments for neurodegenerative diseases by getting drugs through the blood-brain barrier, it will give humanity hope of creating a future where degenerative diseases can no longer rob people of their dignity in their last years of life.
Alongside this meaningful purpose, Scottish Mortgage believes the company has numerous qualities that position it for growth:
- Scale of opportunity: One in three people aged 65 or over in the US dies with Alzheimer’s or another form of dementia
- Expertise: Denali’s leadership has deep scientific expertise, particularly in neurodegenerative diseases
- Broad portfolio: With 10 drugs currently in development, this reduces the risk caused by any one drug failing during clinical trials
- Initial success: Denali’s most advanced trial for Hunter’s disease has shown promising results
- Strategic partnerships: Working with companies such as Sanofi has led to $1.3bn in upfront payments that cover programme costs while allowing Denali to maintain significant control
If Denali succeeds in tackling one of the most significant medical challenges of our time, it could have a far-reaching impact on patients and investors.
About the author - Claire Shaw
Portfolio Director
Claire Shaw is a portfolio director and plays a prominent role in servicing Scottish Mortgage’s UK shareholder base. Before joining in 2019, she spent over a decade as a fund manager with a focus on managing European equity portfolios for a global client base. With a background in analysing companies and communicating investment ideas, Claire is also responsible for creating engaging content that makes the Scottish Mortgage portfolio accessible to all its shareholders. Beyond that, she works closely with the managers, meeting with portfolio companies and conducting in-depth portfolio discussions with shareholders.
Regulatory Information
This content was produced and approved at the time stated and may not have been updated subsequently. It represents views held at the time of production and may not reflect current thinking. Read our Legal and regulatory information for further details.
A Key Information Document is available by visiting our Documents page. Any images used in this content are for illustrative purposes only.
This content does not constitute, and is not subject to the protections afforded to, independent research. Baillie Gifford and its staff may have dealt in the investments concerned. The views expressed are not statements of fact and should not be considered as advice or a recommendation to buy, sell or hold a particular investment.
Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). The investment trusts managed by Baillie Gifford & Co Limited are listed on the London Stock Exchange and are not authorised or regulated by the FCA.
Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 (BGA) holds a Type 1 licence from the Securities and Futures Commission of Hong Kong to market and distribute Baillie Gifford’s range of collective investment schemes and closed-ended funds such as investment trusts to professional investors in Hong Kong.
Baillie Gifford Asia (Singapore) Private Limited (BGAS) is regulated by the Monetary Authority of Singapore as a holder of a capital markets services licence to conduct fund management activities for institutional investors and accredited investors in Singapore. BGA and BGAS are wholly owned subsidiaries of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co.
Europe
Scottish Mortgage Investment Trust PLC (the “Company”) is an alternative investment fund for the purpose of Directive 2011/61/EU (the “AIFM Directive”). Baillie Gifford & Co Limited is the alternative investment fund manager (“AIFM”) of the Company and has been authorised for marketing to Professional Investors in this jurisdiction.
This content is made available by Baillie Gifford Investment Management (Europe) Limited (“BGE”), which has been engaged by the AIFM to carry out promotional activities relating to the Company. BGE is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. BGE also has regulatory permissions to perform promotional, advisory and Individual Portfolio Management activities. BGE has passported its authorisations under the mechanisms set out in the AIFM Directive.
Belgium
The Company has not been and will not be registered with the Belgian Financial Services and Markets Authority (Autoriteit voor Financiële Diensten en Markten / Autorité des services et marchés financiers) (the FSMA) as a public foreign alternative collective investment scheme under Article 259 of the Belgian Law of 19 April 2014 on alternative collective investment institutions and their managers (the Law of 19 April 2014). The shares in the Company will be marketed in Belgium to professional investors within the meaning the Law of 19 April 2014 only. Any offering material relating to the offering has not been, and will not be, approved by the FSMA pursuant to the Belgian laws and regulations applicable to the public offering of securities. Accordingly, this offering as well as any documents and materials relating to the offering may not be advertised, offered or distributed in any other way, directly or indirectly, to any other person located and/or resident in Belgium other than to professional investors within the meaning the Law of 19 April 2014 and in circumstances which do not constitute an offer to the public pursuant to the Law of 19 April 2014. The shares offered by the Company shall not, whether directly or indirectly, be marketed, offered, sold, transferred or delivered in Belgium to any individual or legal entity other than to professional investors within the meaning the Law of 19 April 2014 or than to investors having a minimum investment of at least EUR 250,000 per investor.
Germany
The Trust has not offered or placed and will not offer or place or sell, directly or indirectly, units/shares to retail investors or semi-professional investors in Germany, i.e. investors which do not qualify as professional investors as defined in sec. 1 (19) no. 32 German Investment Code (Kapitalanlagegesetzbuch – KAGB) and has not distributed and will not distribute or cause to be distributed to such retail or semi-professional investor in Germany, this document or any other offering material relating to the units/shares of the Trust and that such offers, placements, sales and distributions have been and will be made in Germany only to professional investors within the meaning of sec. 1 (19) no. 32 German Investment Code (Kapitalanlagegesetzbuch – KAGB).
Luxembourg
Units/shares/interests of the Trust may only be offered or sold in the Grand Duchy of Luxembourg (Luxembourg) to professional investors within the meaning of Luxembourg act by the act of 12 July 2013 on alternative investment fund managers (the AIFM Act). This document does not constitute an offer, an invitation or a solicitation for any investment or subscription for the units/shares/interests of the Trust by retail investors in Luxembourg. Any person who is in possession of this document is hereby notified that no action has or will be taken that would allow a direct or indirect offering or placement of the units/shares/interests of the Trust to retail investors in Luxembourg.
Switzerland
The Trust has not been approved by the Swiss Financial Market Supervisory Authority (“FINMA”) for offering to non-qualified investors pursuant to Art. 120 para. 1 of the Swiss Federal Act on Collective Investment Schemes of 23 June 2006, as amended (“CISA”). Accordingly, the interests in the Trust may only be offered or advertised, and this document may only be made available, in Switzerland to qualified investors within the meaning of CISA. Investors in the Trust do not benefit from the specific investor protection provided by CISA and the supervision by the FINMA in connection with the approval for offering.
Singapore
This content has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this content and any other content or material in connection with the offer or sale, or invitation for subscription or purchase, of the Trust may not be circulated or distributed, nor may be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act 2001, as modified or amended from time to time (SFA)) pursuant to Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
Where the Trust is subscribed or purchased under Section 275 by a relevant person which is:
(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section 275 except:
(1) to an institutional investor or to a relevant person or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(c)(ii) of the SFA,
(2) where no consideration is or will be given for the transfer;
(3) where the transfer is by operation of law; or
(4) pursuant to Section 276(7) of the SFA or Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.
